In clinical orthopedic practice, bone defect repair has long presented enormous challenges. Autologous bone transplantation, though regarded as the "gold standard", is limited by donor-site morbidity and insufficient sources. Meanwhile, conventional artificial bone materials often fail to meet multiple demands simultaneously, including mechanical support, degradation compatibility, and osteogenic induction and regeneration. Today, a major breakthrough has emerged for this dilemma — the approval and launch of Bongolle® Magnesium-containing Biodegradable Polymer Bone Repair Materials (hereafter Bongolle®) offers a brand-new solution for clinical bone defect repair.

 

The research and development of Bongolle® was led by Professor Qin Ling, Chief Scientist of Jingcheng Medical, Foreign Member of the Academia Europaea, Member of the American Institute for Medical and Biological Engineering, and Professor at the Faculty of Medicine, The Chinese University of Hong Kong, together with Researcher Lai Yuxiao, Deputy Director of the Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, and Executive Director of the Translational Medicine Research and Development Center. Jointly with the R&D team of Jingcheng Medical, they overcame three core technical bottlenecks after 15 years of intensive research. Featuring an innovative ternary composite design, the product marks the world’s first application of ultra-low-temperature 3D printing manufacturing technology, fully leveraging the bone repair advantages of degradable metallic magnesium. It precisely resolves critical clinical challenges such as regulating material degradation rate, matching mechanical properties, and inducing osteogenic activity.

 

 

Jingcheng Medical has long upheld the philosophy of "Excellent Physicians with Sincere Dedication", driven by original innovation and guided by clinical needs, committed to achieving domestic substitution of high-end medical devices. As a milestone achievement of the company’s 15-year innovation journey, Bongolle® not only conquers key "bottleneck" technologies but also significantly enhances China’s international competitiveness in bone repair therapy. The product has been granted more than 20 patents and won numerous authoritative domestic and international awards, including the Silver Medal at the 45th International Exhibition of Inventions of Geneva, the China Patent Silver Award, and the Gold Award for Orthopedic Innovation and Clinical Translation Achievement at the inaugural Journal of Orthopaedic Translation (JOT) Awards, earning wide recognition for its technological innovation and clinical value.

 

The successful launch of Bongolle® fills the technological gap in magnesium-based bone repair materials in China, marking a major breakthrough in the innovation of China’s high-end medical devices. Going forward, Jingcheng Medical will build a diversified "1+X" development strategy centered on magnesium-based material technology: vertically deepen the orthopedic field and continuously optimize material properties; horizontally expand into medical sectors including dentistry, neurosurgery, and cardiovascular medicine; and actively foster a global industrial ecosystem. On one hand, it will deepen collaborative innovation with research institutions in the Guangdong-Hong Kong-Macao Greater Bay Area; on the other, accelerate global market deployment to bring this "Chinese Solution" with fully independent intellectual property rights to patients worldwide.